ASH 2023 Conference Round Up: CAR-T Cell Therapies Raise Safety Concerns While Progress In Combination Therapies Continues
Pharmaceuticals / United States / Thu 21 Dec, 2023
Key View
- Safety concerns continue to be a major challenge for CAR-T therapies, potentially affecting future regulatory approvals and widespread clinical adoption.
- Recent clinical data suggest a revival of AbbVie and J&J’s Imbruvica in mantle cell lymphoma, following an earlier withdrawal of the drug.
- Seagen's Adcetris and Bristol Myers